Investors & Media
Corporate Profile
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of therapeutics that target the deregulated transcription that cause cancer and autoimmune diseases. Led by an experienced management team that possesses deep expertise in transcriptional regulation, computational and chemical biology, drug discovery platform technologies, and computational and medicinal chemistry, we have developed a pipeline that includes a clinical-stage candidate and two preclinical-stage candidates.
Market Cap
$
Minimum 15 minutes delayed. Source:
